Hemamalini Karpurapu, MD
Hematology & Oncology · Weirton, WVNPI 1164689618
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,330 of the $2,913 with a category attached, or 80.0%. It is spread thinly across 32 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,097 and has fallen 97.9% since, to $43 in 2025.
Across 157 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$351
- Pfizer$298
- E.r. Squibb & Sons, L.L.C.$275
- Novartis$228
- Seagen Inc.$138
- Bristol Myers Squibb$116
- plus $2K from 26 others
What the payments were for
- Food & beverage$2,33080%
- Education$58320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 14 | $351 |
| Pfizer | 22 | $298 |
| E.r. Squibb & Sons, L.L.C. | 21 | $275 |
| Novartis | 12 | $228 |
| Seagen Inc. | 4 | $138 |
| Bristol Myers Squibb | 7 | $116 |
| AstraZeneca | 5 | $111 |
| AbbVie | 1 | $100 |
| Sanofi | 6 | $99 |
| Boehringer Ingelheim | 4 | $94 |
| Daiichi Sankyo Inc. | 5 | $88 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $87 |
| Incyte Corporation | 5 | $82 |
| Lilly USA, LLC | 4 | $74 |
| Tesaro, Inc. | 4 | $74 |
| Bayer | 4 | $73 |
| Johnson & Johnson(2 entities) | 4 | $70 |
| Astellas Pharma US Inc | 3 | $67 |
| Eisai Inc. | 3 | $59 |
| Tersera Therapeutics LLC | 2 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Myovant Sciences Inc. | 2 | $48 |
| Gilead(2 entities) | 3 | $41 |
| AMAG Pharmaceuticals, Inc. | 2 | $37 |
| GSK | 2 | $36 |
| Merck | 2 | $33 |
| Verastem, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Exelixis Inc. | 2 | $23 |
| Shionogi Inc | 1 | $22 |
| Genentech USA, Inc. | 1 | $17 |
| EMD Serono, Inc. | 1 | $13 |
How this compares
$2,913 in reported general payments places this provider in the 65th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 24 | $345,944 |
| PromactaEltrombopag Olamine | 24 | $285,320 |
| TasignaNilotinib Hcl | 13 | $256,367 |
| IbrancePalbociclib | 11 | $179,319 |
| NubeqaDarolutamide | 11 | $114,738 |
| XareltoRivaroxaban | 30 | $46,390 |
| EliquisApixaban | 42 | $38,597 |
| Exemestane | 68 | $8,233 |
| Letrozole | 163 | $3,284 |
| Anastrozole | 123 | $1,891 |
| Prochlorperazine Maleate | 77 | $896 |
| Hydroxyurea | 82 | $845 |
| Gabapentin | 61 | $795 |
| Acyclovir | 41 | $563 |
| Dexamethasone | 57 | $494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta, Tasigna | $228 | $541,68737 claims |
| PfizerIbrance, Eliquis | $298 | $217,91653 claims |
| BayerNubeqa | $73 | $114,73811 claims |
| Johnson & JohnsonXarelto | $70 | $46,39030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 72 hematology & oncology providers in West Virginia.
Other hematology & oncology in Weirton
- Damian SilberminsHuntington$277K
- Abraham KanateMorgantown$169K
- Salman OsmanBridgeport$118K
- Ashkan EmadiMorgantown$88K
- Konstantinos SdrimasMorgantown$81K
- Arvinder BirHuntington$74K
- Bhavana BhatnagarWheeling$72K
- Ihtishaam QaziMorgantown$18K
- Matias ValsecchiHuntington$17K
- Sonikpreet AulakhMorgantown$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.